<DOC>
	<DOCNO>NCT01956825</DOCNO>
	<brief_summary>The purpose study determine whether dual therapy amino acid L-CARNITINE magnesium effect reduce liver fat content patient non alcoholic fatty liver disease ( NAFLD ) .</brief_summary>
	<brief_title>The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver</brief_title>
	<detailed_description>The purpose study determine whether dual therapy amino acid L-CARNITINE magnesium effect reduce liver fat content patient non alcoholic fatty liver disease . study interventional one 60 patient definition non alcoholic fatty licer disease ( NAFLD ) divide randomly ( double blind ) 2 group : group 1 : `` study group '' . receive product ( flavoured water ) contain L-CARNITINE magnesium . group 2 : control . receive placebo . regular water . Length trial - 12 week . The patient follow weekly base variuos parameter compare ( weight , lipid profile , insulin resistance etc. ) . `` fibrotest '' use begin trial end ( week 12 ) compare fat content treatment .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>age &gt; 18 , &lt; 80 evidence non alcoholic fatty liver disease age &lt; 18 , &gt; 80 pregnancy renal failure congestive heart failure active malignancy liver disease etiology non alcoholic fatty liver disease ( NAFLD ) . hypothyroidism/cushing total prenteral nutrition ( TPN ) last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>non alcoholic fatty liver disease</keyword>
	<keyword>LCARNITINE amino acid</keyword>
	<keyword>magnesium</keyword>
	<keyword>fat content</keyword>
</DOC>